



Cronfa - Swansea University Open Access Repository

This is an author produced version of a paper published in: *Brain*

Cronfa URL for this paper: http://cronfa.swan.ac.uk/Record/cronfa38246

Paper:

Fry, A., Fawcett, K., Zelnik, N., Yuan, H., Thompson, B., Shemer-Meiri, L., Cushion, T., Mugalaasi, H., Sims, D., et. al. (2018). De novo mutations in GRIN1 cause extensive bilateral polymicrogyria. *Brain* http://dx.doi.org/10.1093/brain/awx358

Released under the terms of a Creative Commons Attribution License (CC-BY).

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

http://www.swansea.ac.uk/library/researchsupport/ris-support/



De novo mutations in GRINI cause extensive bilateral polymicrogyria

Andrew E. Fry,^{1,2,*} Katherine A. Fawcett,^{3,*} Nathanel Zelnik,^{4,5} Hongjie Yuan,^{6,7} Belinda A. N. Thompson,^{2,8} Lilach Shemer-Meiri,⁴ Thomas D. Cushion,² Hood Mugalaasi,¹ David Sims,³ Neil Stoodley,⁹ Seo-Kyung Chung,¹⁰ Mark I. Rees,¹⁰ Chirag V. Patel,¹¹ Louise A. Brueton,¹² Valérie Layet,¹³ Fabienne Giuliano,¹⁴ Michael P. Kerr,^{15,16} Ehud Banne,¹⁷ Vardiella Meiner,¹⁸ Tally Lerman-Sagie,¹⁹ Katherine L. Helbig,²⁰ Laura H. Kofman,²¹ Kristin M. Knight,²¹ Wenjuan Chen,^{6,22} Varun Kannan,⁶ Chun Hu,⁶ Hirofumi Kusumoto,⁶ Jin Zhang,^{6,23} Sharon A. Swanger,⁶ Gil H. Shaulsky,⁶ Ghayda M. Mirzaa,^{24,25} Alison M. Muir,²⁴ Heather C. Mefford,²⁴ William B. Dobyns,^{24,25,26} Amanda B. Mackenzie,⁸ Jonathan G. L. Mullins,²⁷ Johannes R. Lemke,²⁸ Nadia Bahi-Buisson,²⁹ Stephen F. Traynelis,^{6,7} Heledd F. Iago²⁷ and Daniela T. Pilz^{2,30}

*These authors contributed equally to this work.

Polymicrogyria is a malformation of cortical development. The aetiology of polymicrogyria remains poorly understood. Using whole-exome sequencing we found *de novo* heterozygous missense *GRIN1* mutations in 2 of 57 parent-offspring trios with polymicrogyria. We found nine further *de novo* missense *GRIN1* mutations in additional cortical malformation patients. Shared features in the patients were extensive bilateral polymicrogyria associated with severe developmental delay, postnatal microcephaly, cortical visual impairment and intractable epilepsy. *GRIN1* encodes GluN1, the essential subunit of the *N*-methyl-D-aspartate receptor. The polymicrogyria-associated *GRIN1* mutations tended to cluster in the S2 region (part of the ligand-binding domain of GluN1) or the adjacent M3 helix. These regions are rarely mutated in the normal population or in *GRIN1* patients without polymicrogyria. Using two-electrode and whole-cell voltage-clamp analysis, we showed that the polymicrogyria-associated *GRIN1* mutations significantly alter the *in vitro* activity of the receptor. Three of the mutations increased agonist potency while one reduced proton inhibition of the receptor. These results are striking because previous *GRIN1* mutations have generally caused loss of function, and because *N*-methyl-D-aspartate receptor agonists have been used for many years to generate animal models of polymicrogyria. Overall, our results expand the phenotypic spectrum associated with *GRIN1* mutations and highlight the important role of *N*-methyl-D-aspartate receptor signalling in the pathogenesis of polymicrogyria.

- 1 Institute of Medical Genetics, University Hospital of Wales, Cardiff CF14 4XW, UK
- 2 Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK
- 3 MRC Computational Genomics Analysis and Training Programme (CGAT), MRC Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
- 4 Pediatric Neurology Unit, Carmel Medical Center, Haifa, Israel
- 5 Bruce and Ruth Rappaport Faculty of Medicine, Technion, Haifa, Israel
- 6 Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA 30322, USA
- 7 Center for Functional Evaluation of Rare Variants (CFERV), Emory University School of Medicine, Atlanta, GA 30322, USA
- 8 Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK
- 9 Department of Neuroradiology, North Bristol NHS Trust, Frenchay Hospital, Bristol BS16 1LE, UK

Received July 16, 2017. Revised October 17, 2017. Accepted November 14, 2017.

[©] The Author(s) (2018). Published by Oxford University Press on behalf of the Guarantors of Brain.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

2 | BRAIN 2018: Page 2 of 15

- 10 Neurology and Molecular Neuroscience Research, Institute of Life Science, Swansea University Medical School, Swansea University, Swansea SA2 8PP, UK
- 11 Genetic Health Queensland, Royal Brisbane and Women's Hospital Campus, Herston, Brisbane, Queensland 4029, Australia
- 12 West Midlands Regional Genetics Service, Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham B15 2TG, UK
- 13 Service de Génétique Médicale, Groupe Hospitalier du Havre, Hôpital Jacques Monod, Le Havre, France
- 14 Service de Génétique Médicale, Centre Hospitalier Universitaire de Nice, Nice, France
- 15 MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK
- 16 Learning Disabilities Directorate, Abertawe Bro Morgannwg University NHS Trust, Treseder Way, Caerau, Cardiff CF5 5WF, UK
- 17 Clinical Genetics Institute, Kaplan Medical Centre, Rehovot, Israel
- 18 Department of Genetics and Metabolic Diseases, Hadassah-Hebrew University Hospital, Jerusalem, Israel
- 19 Pediatric Neurology Unit, Wolfson Medical Centre, Holon, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- 20 Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- 21 Kaiser Permanente Mid-Atlantic States, McLean, VA 22102, USA
- 22 Department of Neurology, Xiangya Hospital, Central South University, Changsha 410013, China
- 23 Department of Neurology, the First Hospital of Shanxi Medical University, Taiyuan, 030001, China
- 24 Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
- 25 Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98195, USA
- 26 Department of Neurology, University of Washington, Seattle, WA 98195, USA
- 27 Genome and Structural Bioinformatics Group, Institute of Life Science, Swansea University, Singleton Park, Swansea SA2 8PP, UK
- 28 Institute of Human Genetics, University Medical Center Leipzig, Leipzig 04103, Germany
- 29 Imagine Institute, INSERM UMR-1163, Laboratory Genetics and Embryology of Congenital Malformations, Paris Descartes University, Paris, France
- 30 West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK

Correspondence to: Dr Andrew E. Fry

Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK E-mail: fryae@cardiff.ac.uk

Keywords: polymicrogyria; GRIN1; GluN1; NR1; N-methyl-D-aspartate receptor

Abbreviations: EC_{50} = concentration of agonist required for half-maximal effect; IC_{50} = concentration of antagonist required for half-maximal inhibition; MCD = malformation of cortical development; NMDA = *N*-methyl-D-aspartate; RMSD = root-mean-square deviation

Introduction

Malformations of cortical development (MCDs) are a spectrum of brain abnormalities that occur due to disruption of the intricate developmental processes that form the cerebral cortex. Although rare, MCDs have a major impact on the lives of patients and their families. Polymicrogyria is a subtype of MCD characterized, macroscopically, by an excessive number of small cortical folds (gyri). At a microscopic level, polymicrogyria is associated with abnormal cortical architecture including thinning or loss of cortical layers (Squier and Jansen, 2014; Jansen et al., 2016). The clinical effects of polymicrogyria depend on the extent and regions of the brain affected. Common consequences include intellectual disability, epilepsy, spasticity and cortical visual impairment (Stutterd and Leventer, 2014). Polymicrogyria can result from non-genetic events such as hypoxic-ischaemic insults or congenital infections. In addition, a range of chromosomal and single-gene disorders have been identified in polymicrogyria patients (Jansen and Andermann, 2005; Stutterd and Leventer, 2014). Despite these discoveries, the underlying cause of the malformation remains unknown in the majority of patients.

Polymicrogyria is usually a sporadic disorder, with most patients having no family history. Polymicrogyria also causes a significant loss of reproductive fitness. This suggests a role for *de novo* mutations in the aetiology of the disorder. Recent candidate gene and exome sequencing studies have shown that *de novo* mutations cause polymicrogyria in some patients (Jaglin et al., 2009; Riviere et al., 2012; Mirzaa et al., 2014). Based on these observations we took the approach of exome sequencing in a cohort of 57 parent-offspring trios. This strategy led us to identify two likely causal variants in GRIN1 in patients with extensive bilateral polymicrogyria. GRIN1 encodes GluN1, the obligatory subunit of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor that is highly expressed in the foetal brain (Law et al., 2003). Mutations in GRIN2B, a gene that encodes a different NMDA receptor subunit, have recently been reported in MCD patients (Platzer et al., 2017). Therefore, having observed two de novo GRIN1 mutations in patients with polymicrogyria, we searched for additional GRIN1 mutations in MCD patients. Furthermore, we examined the functional impact of polymicrogyria-associated GRIN1

mutations by computer-based protein structure modelling and *in vitro* electrophysiological analysis.

Materials and methods

Patients

Patients 1 and 2 were part of a cohort of 57 unrelated proband-parent trios recruited from Clinical Genetic and Paediatric Neurology clinics around the UK. All probands had polymicrogyria demonstrated by MRI and confirmed by review of the neuroradiology. The probands had no known cause for their polymicrogyria and normal array comparative genome hybridization. Parents were judged to be unaffected based on history and a brief physical examination. Most parents had not undergone brain imaging. For more details about the UK cohort see Supplementary Table 1. The study was approved by the Research Ethics Committee for Wales (09/MRE09/51). Informed consent was obtained from all participants (or their parents/legal guardians) prior to testing. Patients 3, 4, and 6-11 were ascertained through a request to collaborators and members of the European Network on Brain malformations looking for similar patients. Patients 3 and 4 underwent trio-based whole exome sequencing as part of an ongoing research program in France. Patients 6-8 had trio-based exome sequencing performed during their clinical diagnostic workup. Patients 9-11 were part of a cohort of 211 polymicrogyria patients who underwent targeted sequencing of the GRIN1 gene as part of a US-based research program. Patient 5 had trio-based whole exome sequencing performed on a clinical basis. He was ascertained due to appearing in a poster at the European Paediatric Neurology Society Congress 2015.

Exome sequencing and in silico prediction

Standard approaches to exome sequencing and variant filtering were used. Detailed descriptions are given in the Supplementary material. Predictions of the functional impact of the *de novo* mutations were made by a range of analysis programs. These included PhyloP (Pollard *et al.*, 2010), SIFT (Kumar *et al.*, 2009), PolyPhen-2 (Adzhubei *et al.*, 2010), MutationTaster (Schwarz *et al.*, 2014), CADD v1.3 (Kircher *et al.*, 2014) and M-CAP (Jagadeesh *et al.*, 2016). We searched the ExAC database for each variant (release 0.3, 14 January 2016) (Lek *et al.*, 2016). Genomic coordinates are based on genome build hg19/GRCh37 (February 2009). Coding and protein positions of the *GRIN1* mutations are based on GenBank accession codes NM_007327.3 (ENST00000371 561.3) and NP_015566.1 respectively.

Homology modelling

Structural modelling of wild-type and mutant GluN1, and wild-type GluN2A proteins was carried out using a previously-described homology-based modelling pipeline (Mullins, 2012). This approach uses the solved structure of a homologous template to model the native folds of a target sequence. The target sequences selected were wild-type GluN1 (based on

Q05586, Uniprot Isoform 3 FASTA file) and wild-type GluN2A (based on Q12879, Uniprot Isoform 1 FASTA file). The template for both O05568 and O12879 was the crystal structure of the GluN1a/GluN2B NMDA receptor (4PE5 chain A) from Rattus norvegicus (Karakas and Furukawa, 2014). The 4PE5 chain A contains the amino terminal domain, agonist binding domain, and transmembrane domain of the wildtype channel tetramer. We constructed our models using two GluN1 and two GluN2A subunits arranged as 1-2-1-2. Target and template underwent structural and consensus alignment using T-Coffee (Notredame et al., 2000). Homology modelling was performed by MODELLER (Webb and Sali, 2016). The putative structure was refined to improve the accuracy of non-conserved regions, optimize bond geometries and remove unfavourable contacts. Structural models were viewed and analysed using the UCSF Chimera software (https://www.cgl. ucsf.edu/chimera/) (Pettersen et al., 2004). Each mutant receptor was superimposed onto the wild-type model. The effects on the transmembrane helices were assessed by measuring the displacement, between the two models, of residues at the ends of each helix (from alpha carbon atoms). The residues were 559, 581, 615, 606, 655, 630, 810 and 828. The superimposed models were also used to calculate root-mean-square deviation (RMSD) values for nine domains (using all backbone atoms in the specified residues): amino terminal (residues 23-394), first and second ligand binding domains (S1 and S2; residues 395-544 and 658-808, respectively), transmembrane domains one to four (M1-M4; residues 560-580, 606-615, 637-657, and 813-833), DRPEER motif (658-663) and SYTANLAAF motif (646-654). UCSF Chimera FindHBond function (using the default relaxation) was used to predict hydrogen bonding between the glycine ligand and the glycine-binding residues of GluN1. UniProt lists these as 516-518, 523, 688 and 732.

Expression plasmids and mutagenesis

For two-electrode voltage clamp recordings, the cDNA for human wild-type NMDA subunits GluN1, GluN2A, and GluN2B (GenBank accession codes: NP 015566, NP 000824 and NP 000825, respectively) were subcloned into pCI-neo (Hedegaard et al., 2012). Mutant GluN1-Y647C, GluN1-R659T, GluN1-N674I, GluN1-D789N and GluN1-R794Q were generated by site-directed mutagenesis using the QuikChangeTM protocol with Pfu DNA polymerase (Agilent Technologies). The parental strand was replicated with the desired mismatch incorporated into the primer (Yuan et al., 2005). Methylated parental DNA template was digested with Dpn I. The nicked double-stranded mutant DNA was transformed into TOP10 Competent Cells (Life Technologies). The mutations were verified by sequencing through the region of the mutations. For whole-cell voltage clamp recordings the cDNA for human wild-type GRIN1 and GRIN2B (Myc-DDK-tagged, based on GenBank accession codes NM_00 7327 and NM_000834, respectively) were subcloned into pCMV6-Entry (OriGene Technologies, catalogue numbers RC216458 and RC223623). Mutant GluN1-N674I was generated in pCMV6-GluN1 by site-directed mutagenesis using the QuikChange[™] mutagenesis kit as described above and verified by Sanger sequencing.

Two-electrode voltage clamp recordings

Two-electrode voltage clamp recordings were performed as previously described (Hansen et al., 2013; Yuan et al., 2014; Chen et al., 2017b). Briefly, coding RNA for wild-type and mutant GluN1 was synthesized in vitro from linearized template cDNA and injected into Xenopus laevis oocytes (Ecocyte). Following injection, the oocytes were stored at 15-19°C in Barth's solution containing (in mM) 88 NaCl, 2.4 NaHCO₃, 1 KCl, 0.33 Ca(NO₃)₂, 0.41 CaCl₂, 0.82 MgSO₄ and 5 Tris/HCl (pH 7.4 with NaOH). Voltage-clamp recordings were performed 2-4 days post-injection at room temperature (23°C). The recording solution contained (in mM) 90 NaCl, 1 KCl, 10 HEPES, 0.5 BaCl₂ and 0.01 EDTA (pH 7.4 with NaOH). Voltage and current electrodes were filled with 0.3 and 3.0 M KCl, respectively, and current responses were recorded at a holding potential of -40 mV (unless otherwise stated). Data acquisition and voltage control were accomplished with a two-electrode voltage-clamp amplifier (OC725, Warner Instrument). NMDA receptor agonists (glutamate or glycine) and antagonists (Mg^{2+} or H^+) were applied to the oocvte using a computer-controlled eight-modular valve positioner (Digital MVP Valve, Hamilton). Glutamate $(100 \,\mu\text{M})$ and glycine $(100 \,\mu\text{M})$ were used in all oocyte experiments unless otherwise stated. The agonist concentration-response curves were fitted with:

Response (%) =
$$100/(1 + (EC_{50}/[agonist])^{nH})$$
 (1)

where EC_{50} is the agonist concentration that elicited a halfmaximal response and *nH* is the Hill slope. IC₅₀ values for Mg²⁺ were obtained by fitting the concentration-response data with:

Response (%) =
$$(100 - minimum)/$$
 (2)
 $\left(1 + \left([modulator]/IC_{50}\right)^{nH}\right) + minimum$

where IC_{50} is the concentration that produces a half-maximal effect, and *minimum* is the degree of residual inhibition at a saturating concentration of Mg²⁺. Data were expressed as mean \pm standard error of the mean (SEM).

Preparation and transfection of HEK 293 cells

HEK 293 cells (ATCC) were plated onto glass coverslips coated in 100 µg/ml poly-D-lysine and incubated at 37°C (5% CO2 in DMEM/F12 1:1 media) supplemented with 10% foetal bovine serum, 2 mM glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin. The cells were co-transfected with plasmid cDNAs encoding green fluorescent protein (GFP), GluN2B, and GluN1 or GluN1-N674I. For transfection, media was changed to S-MEM media with 1% foetal bovine serum, 0.5 mM glutamine and 0.5 mM CaCl₂. Mixed pCMV plasmid DNA (0.25 µg each of GluN2B, GluN1 or GluN1-N674I, and 0.125 µg nucGFP) with 50 µl Opti-MEM^{IM} and 1 µl LipofectamineTM 2000 (Life Technologies) was added to each well and the mixture incubated at 37°C for 4h. Media was then changed to transfection media plus 100 µM D-AP5 (R&D systems), a competitive NMDA receptor antagonist. The cells were inspected by fluorescence microscope 16-24 h

post-transfection. Cells expressing GFP were used for wholecell voltage-clamp recordings.

Whole-cell voltage clamp recordings

Whole-cell voltage clamp recordings were performed as previously described (Jiang et al., 2005; Thompson et al., 2012). Membrane potential of transfected cells were held at -60 mV (at room temperature, 23°C) using a patch clamp amplifier (EPC10, HEKA). Borosilicate glass microelectrodes, 5-5.5 MΩ were filled with intracellular solution containing (in mM) 117 KCl, 10 NaCl, 11 HEPES, 11 EGTA, 2 MgCl₂, 1 CaCl₂, 2 Na₂ATP (pH 7.2 with KOH). The extracellular solution contained (in mM) 135 NaCl, 5 KCl, 5 HEPES, 10 glucose, 1.2 MgCl₂ and 1.25 CaCl₂ (pH 7.4 with NaOH). Solution exchange was achieved with a rapid solution changer (BioLogic) and data collected using PatchMaster software (HEKA). Peak currents were defined as the maximal amplitude of response during the agonist application; responses were plotted as current density (pA/pF). Concentration-response curves were constructed and fitted by Equation 1 using Prism 7.

Results

GRIN1 mutations in patients with polymicrogyria

We performed whole-exome sequencing in 57 unrelated individuals with polymicrogyria and their unaffected parents. Two of the polymicrogyria patients (Patients 1 and 2) had de novo missense mutations in GRIN1 [c.2021A>T, p.(Asn674Ile) and c.2381G>A, p.(Arg794Gln)]. Apart from known polymicrogyria genes, GRIN1 was the only gene with *de novo* mutations in more than one patient. (A manuscript describing all de novo mutations in the cohort is in preparation). Given the predicted rate of de novo missense mutations in GRIN1 (from ExAC: 4.4×10^{-5}) the observation of more than one de novo GRIN1 missense mutation in 57 subjects has a P-value of 3.1×10^{-6} (binomial test). This is close to a strict Bonferroni-corrected experiment-wide P-value threshold of 2.5×10^{-6} per gene (Kiezun et al., 2012). We found nine further GRIN1 missense mutations in additional MCD patients (Table 1). The 11 missense mutations were all de novo, affected highlyconserved residues (Supplementary Fig. 1) and in silico predictions suggested they were all deleterious (Supplementary Table 2). Two of the mutations [c.1975C>T,p.(Arg659Trp) and c.2365G>A, p.(Asp789Asn)] were recurrent. Shared clinical features in the live-born patients were severe or profound developmental delay, postnatal microcephaly, cortical visual impairment and treatment-resistant epilepsy. A summary of the clinical features is given in Table 1 (detailed case reports are provided in the Supplementary material). Some previous GRIN1 patients have been noted to have abnormal eye movements resembling oculogyric crises and stereotypic hand movements. At least four of our series had similar features (abnormal

ole I Clinical features of patients with GRINI mutations and polymicrogyria	gyria
I Clinical features of patients with GRINI mutation	olymicro
I Clinical features of patients with GRINI mutation	od pu
I Clinical features of patients with	utatior
I Clinical features of patients with	GRINI
I Clinical	with
I Clinical	patients
I Clinical	of
I Clinical	features
e	
	e

I234567899MaleFemaleFemaleMaleFemaleMaleFemaleMaleFemaleMale $y'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzzzzw/zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzzzzw/zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzzzzw/zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzzzzzw/zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzzzzzw/zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzz'zzzw/zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmzy'zmz'zw'zmzw'zm'zmzw'zm'zmzw'zm'zm'zmzw'zm'zm'zmzw'zm'zm'zmzw'zm'zm'zmzw'zm'zm'zmz'zw'zmzw'zm'zmzw'zm'zm'zmzw'zm'zm'zm'zmzw'zm'zm'zm'zmzw'zm'zm'zm'zmzw'zm'zm'zmzw'zm'zm'zmzw'zm'zmzw$	ient at last view ation	2									
MaleFemaleFemaleMaleFemaleMaleFemaleMaleFemaleMaleMaleat kit 3γ 5 m 2γ 2 w gestation $20 m$ $Died at 14 \gamma$ at on 2γ 5 m <td< th=""><th>at last view ation</th><th>I</th><th>S</th><th>4</th><th>Ŋ</th><th>6</th><th>7</th><th>8</th><th>6</th><th>01</th><th>=</th></td<>	at last view ation	I	S	4	Ŋ	6	7	8	6	01	=
		Female	Female	Male	Male	Female	Male	Female	Male	Male	Female
		2y 5m	4y 7m	19 m	3y 6m	9γ	22 w gestation	20 m	Died at 14 y	17y	Died at 8 y
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											
sno fragrading p.(Nyr647Cys) p.(Asn501le) p.(Asn501le) p.(Asn501le) p.(Asn501le) p.(Arg557Trp) na -5.2 SD -0.9 SD -2.5 SD -0.8 SD na +0.59 SD na stor -5.1 SD -1.15 SD -6.5 SD na -1.6 SD -5.7 SD na stor Good head Not sitting or stor Good head Not sitting or stor Good head Not sitting or stor Severe delay Profound delay Severe delay Not sitting or Not sitting or Not sitting or stor Good head Nor Anore Anore Not sitting or stor	D.(Asn674		c.1975C>T	c.1940A > G	c.2365G > A	c.1652T > C	c.1958C > G	c.1949A>T	c.1975C>T	c.2365G > A	c.1658C>T
nda +0.0 SD -0.9 SD -0.3 SD -0.0 SD nda +0.59 SD nda 5 SD -5.1 SD -1.1 SD -1.5 SD -6.5 SD n/a -1.6 SD -5.7 SD n/a and Severe delay. Profound delay. Severe delay. Non sitting or valking valking or va	· · · · · · · · · · · · · · · · · · ·		p.(Arg659Trp)	p.(Tyr647Cys)	p.(Asp789Asn)	p.(Leu55 I Pro)	p.(Ala653Gly)	p.(Asn650lle)	p.(Arg659Trp)	p.(Asp789Asn)	p.(Ser553Leu)
5 SD -5.1 SD -1.5 SD -1.5 SD -1.6 SD n/a -5.7 SD n/a ound Severe delay. Nor sitting or No		n/a	+ 0.0 SD	-0.9 SD	-2.5 SD	-0.8 SD	n/a	+ 0.59 SD	n/a	-4.9 SD	n/a
oundSevere delay.Profound delay.Severe delay.Severe delay.Severe delay.Severe delay.ay. Not.Good headNot sitting voNot sitting voNot sitting voNot sitting voNot sitting voNot sitting voling.babbling.babbling.Not sitting voAbnormalspeechwith frame.Not sitting voNot sitting voNot sitting voling.babbling.babbling.Not sitting voAbnormalspeechwith frame.Not sitting voNot sitting voallzing.texYesYesYesYesYesYesNot sitting voallzing.YesYesYesYesYesNot sitting voNot sitting voallzing.YesYesYesYesYesYesNot sitting voallzing.SamsInwInwAbnormalNor sitting voNot sitting voallzing.YesYesYesYesYesNot sitting voclonicGeneralizedSpasmsInwInwNor sitting voNot sitting voallzing.YesTonicGeneralizedSpasmsInvYesNot sitting voclonic-clonicSpastic tetra-Spastic tetra-Spastic tetra-Spastic tetra-Mid visiting votittetetra-Spastic tetra-Spastic tetra-Spastic tetra-Not sitting voNot sitting votittetetra-Spastic tetra-Spastic tetra-Spastic tetra-Spastic tetra-Not sitting vo <td></td> <td>-5.2 SD</td> <td>-7.I SD</td> <td>–1.5 SD</td> <td>-6.5 SD</td> <td>n/a</td> <td>—I.6 SD</td> <td>-5.7 SD</td> <td>n/a</td> <td>6.7 SD at</td> <td>-7.1 SD at 3 y</td>		-5.2 SD	-7.I SD	–1.5 SD	-6.5 SD	n/a	—I.6 SD	-5.7 SD	n/a	6.7 SD at	-7.1 SD at 3 y
ound severe delay, severe delay, alloing, babling, rotound delay, wolking, No severe delay, movements, severe delay, severe delay, alloing, rotound delay, wolking, No severe delay, motor sitting or valking, No severe delay, wolking, No severe wolking, No Not sitting or wolking, No Normal sovere No Severe delay, wolking, No severe delay, No severe delay, No No severe delay, No	-		-	-	-	-		-	-	ر ۱6 س	-
χ, Not Good head Not sitting, Valks Not sitting or valking, or valking, No Not sitting or valking, No No<	Development Protound		Protound delay.	Severe delay.	Protound delay.	Severe delay.	n/a	Severe delay.	Severe delay.	severe delay.	severe delay.
ing orcontrol. Nowalking. NoAbnormalspeechwith frame.walking. Nowalking. Nowalking. Noklingbabbling.babbling.movements.development.Stereotypies.babbling.babbling.walking. Noalizing.YesYesYesYesYesYesn/a9 m2 m3 m1 w<1 m	delay. Nu		Not sitting or	Not sitting.	No motor or	Sitting. Walks		Not sitting or	Not sitting or	Not sitting or	Not sitting
Iking, calizing,babbling, babbling,movements.development.Stereotypies.babbling.calizing, calizing,YesYesYesYesYesNaNa $9m$ $2m$ $2m$ $3m$ $1w$ $< 1y$ na Yes na $9m$ $2m$ $2m$ $3m$ $1w$ $< 1y$ na Yes na $6m$ $7m$ $3m$ $1w$ $< 1w$ $< 1m$ $< 1m$ $< 1m$ $6m$ $2m$ $3m$ $1w$ $< 1w$ $< 1m$ $< 1m$ $< 1m$ $6m$ $2m$ $3m$ $1w$ $< 1w$ $< 1m$ $< 1m$ $< 1m$ $6m$ $2m$ $3m$ $1w$ $< 1w$ $< 1m$ $< 1m$ $< 1m$ $6m$ $2m$ $3m$ $1w$ $< 1w$ $< 1m$ $< 1m$ $< 1m$ $6m$ $1m$ $1w$ $1w$ $1w$ $< 1m$ $< 1m$ $< 1m$ $6m$ $1m$ $1w$ $1m$ $1w$ $< 1m$ $< 1m$ $< 1m$ $6m$ $1m$ $1m$ $1m$ $1m$ $1m$ $< 1m$ $< 1m$ $6m$ $1m$ $1m$ $1m$ $1m$ $1m$ $< 1m$ $< 1m$ $6m$ $1m$ $1m$ $1m$ $1m$ $1m$ $1m$ $< 1m$ $6m$ $1m$ $1m$ $1m$ $1m$ $1m$ $1m1m6m1m1m1m1m1m1m1m6m1m1m1m1m1m1m<$	sitting o		walking. No	Abnormal	speech	with frame.		walking. No	walking.	walking.	or walking.
YesYesYesYesYesYesYesNaYesNa 9 m 2 m 3 m 1 w < 1 y n/a Yes n/a 9 m 2 m 3 m 1 w < 1 y n/a Yes n/a clonicGeneralizedSpasmsTonicGrimacingSpasms n/a < 1 m 5 wclonicGeneralizedSpasmsTonicGrimacingSpasms n/a < 1 m < 1 m < 1 m/aclonicGeneralizedSpastic tetra-Spastic tetra-Spastic tetra-Spastic tetra- < 1 m/a < 1 m/a < 1 m/aclonicGeneralizedSpastic tetra-Spastic tetra-Spastic tetra- < 1 m/a < 1 m/a < 1 m/agia, axialhypotoniahypotoniahypotoniahypotoniahypotonia < 1 m/a < 1 m/a < 1 m/acrotilretensive bilat-plegia, axialhypotoniahypotonia < 1 m/a < 1 m/a < 1 m/a < 1 m/anocipitalretensive bilat-plegia, axialhypotoniahypotonia < 1 m/a < 1 m/a < 1 m/anocipitalretensive bilat-plegia, axialhypotoniahypotonia < 1 m/a < 1 m/a < 1 m/anocipitalretensive bilat-plegia, axialhypotoniahypotoniahypotonia < 1 m/a < 1 m/a < 1 m/anocipitalretensive bilat-plegia, axialhypotoniahypotoniahypotonia $< $	walking. Vocalizin		babbling.	movements.	development.	Stereotypies.		babbling.		Vocalizing.	
	7		Yes	Yes	Yes	Yes	n/a	Yes	n/a	Yes	Yes
eMyoclonicGeneralizedSpasmsTonic, gazeTonic,	Seizure onset 6 w	9 m	2 m	3 m	×	<ly <</ly 	n/a	Е V	5 w	m ∧ ∽	2 w
tonic-clonicSpastic tetra-Spastic tetra-ReviationSpastic tetra-Spastic tetra-Spastic tetra-ReviationSpastic tetra-Spastic tetra-Spastic tetra-Spastic tetra-Mild scoliosisplegia, axialplegia, axialplegia, axialplegia, axialplegia, axialMild scoliosishypotoniahypotoniahypotoniahypotoniahypotoniaNipotoniaMild scoliosisteteral PMGeral PMG withPMGeral PMG witheral PMG withPMGeral PMG withketensive bilat-Diffuse bilateralExtensive bilat-Extensive bilat-Extensive bilat-Extensive bilat-Extensive bilat-keteral PMGeral PMG withPMGeral PMG withvin PMG,ning and sul-PMGeral PMG withketeral profigsparingsparingsparingsparingsparingsparingsparingsparingformalThinNormalNormalMildy enlargedNormalNormalNormalMildy enlargedMildy enlargedMildy enlargedNormal <tr< td=""><td>Initial seizure Myoclonic</td><td></td><td></td><td>Tonic</td><td>Grimacing</td><td>Spasms</td><td>n/a</td><td>Tonic, gaze</td><td>Tonic</td><td>Gaze deviation</td><td>Tonic</td></tr<>	Initial seizure Myoclonic			Tonic	Grimacing	Spasms	n/a	Tonic, gaze	Tonic	Gaze deviation	Tonic
Spastic tetra- blegia, axialSpastic tetra- blegia, axialSpastic tetra- blegia, axialSpastic tetra- blegia, axialMid scoliosisplegia, axial hypotoniaplegia, axial hypotoniamid scoliosistateral PMG etteral PMG with occipitaleral PMG with etteral perisyl- etteral perisyl- hormal kin-eral PMG with etteral perisyl- hymotoniamid scoliosismid scoliosistateral PMG etteral PMG with occipitaleral PMG with etteral perisyl- etteraleral PMG with etteral perisyl- etteraleral PMG with hymotoniaeral PMG with hymotoniaeral PMG with etteraleral	type	tonic-clonic						deviation		from 3 y	
plegia, axialplegia, axialplegia, axialplegia, axialplegia, axialhypotoniahypotoniahypotoniahypotoniahypotoniahypotoniaExtensive bilat-Diffuse bilateralExtensive bilat-Bilateral perisyl-honrmal thin-Fronto-parietalExtensive bilat-Extensive bilat-Diffuse bilateralExtensive bilat-Bilateral perisyl-honrmal thin-Fronto-parietalExtensive bilat-keteralPMGeral PMG witheral PMG withvian PMG,ning and sul-PMGeral PMG withketeraloccipitaloccipitalfrontal, parietaleaton of theoccipitalsparingsparingsparingsparingsparingsparingsparingsparingNormalNormalThinNormalNormalMypolasticThinNormalNormalNormaln/aNormalNormalNormalNormalNormalNormalNormaln/aNormalNormalNormalNormalNormal			Spastic tetra-	Pseudobulbar	Spastic tetra-	Spastic tetra-	n/a	Spastic tetra-	Mild scoliosis	Spastic tetra-	Spastic tetra-
hypotoniahypotoniahypotoniahypotoniahypotoniaExtensive bilat-Extensive bilat-Diffuse bilateralExtensive bilat-Extensive bilat-Extensive bilat-Extensive bilat-Diffuse bilateralExtensive bilat-Extensive bilat-Extensive bilat-Extensive bilat-Interval PMGeral PMG witheral PMG witheral PMG witheral PMG witheral PMG withketeraloccipitaleral PMG witheral PMG witheral PMG witheral PMG withwith occipitaloccipitalfrontal, parietalcation of theoccipitaloccipitalsparingsparingsparingsparingsparingsparingsparingNormalNormalThinNormalNormalNormalNormalNormalNormalNormaln/aNormal	plegia, a>		plegia, axial	palsy,	plegia, axial	plegia, axial		plegia, axial		plegia, axial	plegia, axial
Extensive bilat- Diffuse bilateral Extensive bilat- Extensive bilat- Bilateral perisyl- Abnormal thin- Fronto-parietal Extensive bilat- lateral PMG eral PMG with PMG eral PMG with with occipital cotopital frontal, parietal cation of the occipital occipital occipital sparing	hypotoni			hypotonia	hypotonia			hypotonia		hypotonia	hypotonia
lateral PMG eral PMG with PMG. eral PMG with PMG eral PMG with with occipital occipital frontal, parietal cation of the occipital sparing sparing sparing sparing sparing sparing sparing sparing sparing sparing sparing occipital occipital Normal Normal Thin Normal Normal Normal Hypoplastic Thin Normal Normal Mildly enlarged n/a Mildly enlarged Normal Large enlarged Normal Normal Normal Normal Normal Normal Normal Normal	ш	ш	Diffuse bilateral	Extensive bilat-	Extensive bilat-		Abnormal thin-	Fronto-parietal	Extensive bilat-	Diffuse bilateral	Diffuse bilat-
with occipital occipital occipital occipital frontal, parietal cation of the occipital sparing	lateral P			eral PMG with	eral PMG with	vian PMG,	ning and sul-	PMG	eral PMG with	PMG	eral PMG
sparing sparing sparing sparing and temporal cerebral sparing	with occ			occipital	occipital	frontal, parietal	cation of the		occipital		
Normal Normal Thin Normal Normal Cortex Normal Mildy enlarged n/a Mildly enlarged Normal Large Large Moderately enlarged Normal	sparing	sparing		sparing	sparing	and temporal	cerebral		sparing		
Normal Normal Ihin Normal Normal Normal Hypoplastic Ihin Normal Normal Mormal Mildly enlarged Normal Large Large Moderately enlarged Normal Norma Normal Nor						spread	cortex				i
Normal Mildly enlarged n/a Mildly enlarged Mildly enlarged Normal Large Large Moderately enlarged Normal Normal Normal Normal Normal Normal Normal	Ę	Normal	lhin	Normal	Normal	Normal	Hypoplastic	lhin	Normal	Normal	lhin
eniarged Normal Normal Normal Normal Normal Normal Normal Normal		Mildly enlarged	n/a	Mildly enlarged		Normal	Large	Large	Moderately	Enlarged	Enlarged
Normal Normal n/a Normal Abnormal Normal Normal Abnormal Normal									enlarged		
	Hippocampi Normal	Normal	n/a	Normal	Abnormal	Normal	Normal	Abnormal	Normal	Normal	Thin leaves

movements in Patient 4, stereotypic movements in Patient 6, and episodes of gaze deviation in Patients 8 and 10). Abnormal movements may have been present in the other patients but either unreported or misinterpreted (e.g. as seizures or roving eve movements). Magnetic resonance images from all subjects (apart from Patients 3 and 7) were available for review (Fig. 1). The patients demonstrated an extensive bilateral cortical malformation similar in appearance to tubulinopathy- or GRIN2B-associated dysgyria (Platzer et al., 2017). None of the brains have been examined histologically but the magnetic resonance appearance was most consistent with polymicrogyria. The distribution of the polymicrogyria was typically diffuse (frontal, perisylvian, parietal and temporal) and bilateral but with some occipital sparing. Patients 8 and 9 had polymicrogyria in the frontal and parietal regions but the extent of perisylvian involvement was unclear from the available images. Patient 6 had predominantly perisylvian polymicrogyria with some frontal, parietal and temporal involvement (grade 2 bilateral perisylvian polymicrogyria). This milder cortical malformation correlated with the patient's milder phenotype (sitting and walking, but still severely delayed). Additional magnetic resonance findings in the patients were increased extra-axial spaces (particularly anteriorly, 9/11), enlarged lateral ventricles (8/11), reduced white matter volume (9/11), thinning of the corpus callosum (4/11) and abnormal hippocampi (3/11).

Lemke *et al.* (2016) reviewed the MRI findings of 19 previous *GRIN1* patients. None were noted to have polymicrogyria (delayed formation of sulci was observed in one patient with homozygous *GRIN1* nonsense mutations) (Lemke *et al.*, 2016). To ensure our findings were not simply due to differences in the interpretation of radiology we reviewed MRI brain images from four previous non-polymicrogyria patients with *GRIN1* mutations (p.Asp552Glu, p.Met641Ile, p.Gly815Arg and p.Gly827Arg) (Ohba *et al.*, 2015; Lemke *et al.*, 2016). This confirmed the absence of polymicrogyria.

Clustering of polymicrogyriaassociated GRIN1 mutations

We compared the positions of the 11 polymicrogyria-associated *GRIN1* mutations with 16 different heterozygous proven (or likely) *de novo GRIN1* mutations previously reported in 23 patients with non-syndromic intellectual disability and epileptic encephalopathy (Fig. 2) (Lemke *et al.*, 2016). We observed that most polymicrogyria-associated mutations occurred in the S2 domain of GluN1 or the adjacent M3 helix. The proportion of mutation in these two domains (9/11) was greater than expected based on the distribution of previous *GRIN1* mutations (5/23; P = 0.002, Fisher's exact test). Furthermore, no polymicrogyria-associated mutations were observed in M4, a domain where nearly half of all previous mutations were located.

Six polymicrogyria-associated *GRIN1* mutations [p.Arg659Trp (two mutations), p.Asn674Ile, p.Asp789Asn

(two mutations) and p.Arg794Gln] were located in the S2 domain. The S2 domain forms part of the ligand-binding domain of GluN1 and has been shown to be highly intolerant to variation (Ogden *et al.*, 2017). The recurrent p.Arg659Trp mutation is in the DRPEER motif of S2 (residues 658–663). This motif is close to the extracellular end of M3, near the channel pore entrance. Only two previous *GRIN1* mutations have been located in S2 (p.Glu662Lys and p.Ser688Tyr) (Hamdan *et al.*, 2011; Zehavi *et al.*, 2017). Neither patient was reported to have polymicrogyria although the p.Glu662Lys patient only had a CT brain scan (MRI was not done) (Hamdan *et al.*, 2011). CT generally lacks the resolution to detect polymicrogyria.

polymicrogyria-associated GRIN1 mutations Three (p.Tyr647Cys, Asn650Ile and p.Ala653Gly) were in close proximity to the S2 domain in a region of highly-conserved residues at the extracellular end of M3. These residues (646 - 654)are known the Lurcher as motif (SYTANLAAF). This motif is thought to act as the major permeation barrier at the intersection of four M3 helices (Murthy et al., 2012). Different mutations affecting residues 647 and 650 have previously been reported in patients with epileptic encephalopathy (Epi4K Consortium et al., 2013; Ohba et al., 2015). Neither was reported to have polymicrogyria although the p.Tyr647Ser patient only had a CT brain scan. The final two polymicrogyria-associated mutations (p.Leu551Pro and p.Ser553Leu) were located in the S1-M1 linker region. The tertiary structure of GluN1 means the residues are located close to the extracellular end of the M3 helix (Fig. 2). It has recently been proposed that the pre-M1 region is close enough to M3 to interact as a key gating element (Sobolevsky et al., 2009; Chen et al., 2017b; Ogden et al., 2017).

Modelling the structural effects of GRIN1 mutations

We hypothesized that polymicrogyria-associated and previous GRIN1 mutations might have different effects on the structure of GluN1. To study this we developed a 3D model of the GluN1/GluN2A NMDA receptor based on the rat GluN1/GluN2B tetramer (Fig. 2). We simulated models for the nine polymicrogyria-associated GRIN1 mutations and 16 previous GRIN1 mutations. We measured each mutant model in three ways: (i) the displacement, between mutant and wild-type, of the extracellular and intracellular ends of each transmembrane helix; (ii) the displacement, between the mutant and wild-type, of nine key domains. A RMSD value (a measure of average distance between the two superimposed structures) was calculated for each domain; and (iii) the number of hydrogen bonds between the glycine ligand and the glycine-binding residues of GluN1.

Analysis of transmembrane helix positions (Supplementary Table 3) and domain-specific RMSD values (Supplementary Table 4) revealed no consistent differences between previous




Figure 1 Polymicrogyria in patients with *GRIN1* mutations. Axial, midline sagittal and coronal brain magnetic resonance images for Patient I at age 2 months (A-C) and Patient 2 at age 5 months (D-F); axial magnetic resonance images for Patient 4 at age 3 months (G), Patient 5 at age 6 weeks (H) and Patient 6 at age 8 months (I); axial, sagittal and coronal images for Patient 8 at age 3 months (J-L); a coronal image for Patient 9 at age 4 months (M); axial images from Patient 10 at age 8 months (N) and Patient 11 at age 2 months (O). Images B, C and K are T_1 weighted. All other images are T_2 -weighted. The images demonstrate bilateral extensive polymicrogyria (white arrows) more severe anteriorly. Note the increased extra-axial spaces and enlarged lateral ventricles (in most images apart from I) suggesting cerebral volume loss.




Figure 2 Position of the *GRIN1* mutations. (**A**) This ribbon diagram of the GluN1 subunit of the NMDA receptor demonstrates the location of the binding site of glycine in the ligand binding domain, transmembrane helices (M1-M4 in green) and glycine binding residues of GluN1 (orange residues and blue underlined numbers). Mutated residues are in yellow. Polymicrogyria-associated mutations are in red text and previous *GRIN1* mutations are in black text. (**B**) The same ribbon model rotated 90 degrees in the axial plane. (**C**) A model of the C-terminal end of *GRIN1*. In addition to showing M1-M4, the model shows the position of the second ligand binding domain (S2), calmodulin biding domain (CBD) and the C-terminal domain (CTD). Codon position is listed below the model. Heterozygous *GRIN1* variants reported or reviewed by Lemke *et al.* (2016) (non-polymicrogyria, white triangles) are shown above the model. The two yellow triangles represent subjects with CT brain imaging only. Polymicrogyria-associated *GRIN1* mutations (red triangles) cluster in the S2 domain (6/11) or in the adjacent Lurcher motif of M3 (3/11).

and polymicrogyria-associated *GRIN1* mutations. The regions of GluN1 most affected by *GRIN1* mutations in both groups were M2, M3 (particularly the extracellular end) and S2. All *GRIN1* mutants had RMSD values > 2 Å for the S2 domain and DRPEER motif. The extracellular end of the M3 helix (the part of the helix involved in the channel pore entrance) was displaced > 1 Å for all *GRIN1* mutants apart from polymicrogyria-associated p.Asp789Asn (0.67 Å). The p.Asp789Asn mutation stood out from other mutations in causing the least displacement of transmembrane helices (all ≤ 1.01 Å) and the lowest RMSD value for the M3 helix (1.17 Å). The p.Asp789Asn mutation still had its greatest effects on the S2 domain (RMSD 3.06 Å) where it was located. The polymicrogyria-associated p.Leu551Pro and p.Ser553Leu mutations were located in the S1-M1 linker

region but had their greatest effects on the RMSD values of the M2, M3 and S2 domains. On average polymicrogyria-associated mutations generated slightly more hydrogen bonds with glycine (6.8) compared with previous mutations (4.8; P = 0.02, Mann-Whitney U-test) and wild-type (4) (Table 2). However, the effects varied between mutations. All polymicrogyria-associated mutations increased the number of hydrogen bonds with glycine apart from p.Asp789Asn, which formed one less than wild-type.

Impact of GRIN1 mutations on NMDA receptor function

To investigate whether polymicrogyria-associated *GRIN1* mutations influence NMDA receptor function *in vitro* we

GluN1 residue	Pro516	Thr518	Arg523	Ser687	Ser688	Asp732	Bond total
Wild-type	_	××	×	_	×	_	4
Previous GRIN1 mu	utations						
S549R	_	_	× ×	×	×	×	5
D552E	_	_	× ×	_	×	×	4
P557R	_	×	_	_	×	×	3
S560dup	_	×	×	_	× (689)	× (733)	4
G618R	_	_	_	_	××	×	3
G620R	_	$\times \times \times$	_	_	×	×	5
M6411	_	××	××	×	×	××	8
A645S	_	×	××	_	×	_	4
Y647S	_	_	_	×	××	× ×	5
N650K	_	_	_	×	×	×	3
E662K	_	×	×	_	×	×	4
G815R	_	×	×	_	××	×	5
G815V	_	$\times \times \times$	$\times \times \times$	_	×	×	8
F817L	_	_	_	_	××	×	3
G827R	_	××	××	_	×	×	6
R844C	_	××	××	_	×	×	6
Polymicrogyria-asso	ciated GRINI m	utations					
L551P	×	$\times \times \times$	×	_	××	× ×	9
S553L	_	××	××	××	_	_	6
Y647C	_	××	×	×	×	×	6
N650I	_	××	×	×	× ×	×	7
A653G	_	$\times \times \times$	$\times \times \times$	-	×	××	9
R659W	_	××	×	-	× ×	×	6
N674I	_	$\times \times \times$	$\times \times \times$	_	××	××	10
D789N	_	-	_	_	××	×	3
R794Q	-	-	-	×	× ×	× ×	5

Table 2 Effect of GRIN1 mutations on hydrogeneous	drogen bonds between the glycir	ne ligand and the glycine-binding residues of
GluNI		

Number of hydrogen bonds between glycine and specified residues: - (none), \times (one), $\times \times \times$ (two), $\times \times \times$ (three). All predicted hydrogen bonds were < 3 Å in length.

undertook site-directed mutagenesis to introduce five of the GRIN1 mutations (p.Tyr647Cys, p.Arg659Trp, p.Asn674Ile, p.Asp789Asn and p.Arg794Gln) into cDNA encoding human GluN1. We then expressed wild-type and mutant GluN1 with either human wild-type GluN2A or GluN2B in Xenopus oocytes and evaluated the effects of these mutants on pharmacological properties of NMDA receptors by using two-electrode voltage clamp recordings, including agonist potency (glutamate and glycine), as well as magnesium and proton sensitivity. The concentration that produced a half-maximal current response (EC_{50}) was determined by measuring the current response to a range of glutamate (in the presence of 100 µM glycine) and glycine (in the presence of 100 µM glutamate) concentrations at a holding potential of $-40 \,\mathrm{mV}$. The magnesium sensitivity (IC_{50}) was determined by measuring the effect of different magnesium concentrations on agonist-evoked currents (by 100 µM glutamate and 100 µM glycine) at a holding potential of $-60 \,\mathrm{mV}$. The proton sensitivity was evaluated as the percentage of receptor activity at pH 6.8 compared with receptor activity at pH 7.6 (holding potential of -40 mV).

The p.Arg659Trp and p.Arg794Gln mutations had similar effects; both increased the potency (reduced EC₅₀

values) of agonists, and in particular, glutamate. The EC_{50} of mutant receptors was reduced to 10–20% of wild-type levels (Table 3). The potency of glycine was also increased: EC_{50} was 71% of wild-type for GluN1-R794Q/GluN2A, 61% for GluN1-R794Q/GluN2B, 36% for GluN1-R659W/GluN2A and 15% for GluN1-R659W/GluN2B. There were no detectable differences in Mg²⁺ blockade. Proton inhibition was not statistically significant apart from a reduced block in GluN1-R659W/GluN2A (70% mutant versus 52% wild-type).

The p.Tyr647Cys mutation demonstrated a profound increase in the potency of glutamate with an EC₅₀ of just 1.6% of wild-type for GluN1-Y647C/GluN2A and 2.4% for GluN1-Y647C/GluN2B. There was a similarly increased sensitivity to glycine (EC₅₀ 4.6% for GluN1-Y647C/GluN2A; 11.2% for GluN1-Y647C/GluN2B). There was a statistically significant increase in Mg²⁺ blockade for GluN1-Y647C/GluN2A (IC₅₀ 38% of wild-type) but not GluN1-Y647C/GluN2B (IC₅₀ 81% of wild-type) (Table 3). There were also significant but variable effects on proton inhibition: slightly increased in GluN1-Y647C/GluN2A (35% mutant versus 41% wild-type) but reduced in GluN1-Y647C/GluN2B (30% mutant versus 15% wild-type).

Tab	le 3	Summary o	f two-e	lectrode	voltage	clamp	data
-----	------	-----------	---------	----------	---------	-------	------

Constructs	Glu EC₅₀, μM (n)	Mutant/ WT, %	Gly EC ₅₀ , μΜ (n)	Mutant/ WT, %	Mg ²⁺ IC ₅₀ , μΜ (n)	Mutant/ WT, %	%, pH 6.8/ pH 7.6	%, Mutant/ WT
WT GluN1/GluN2A	3.3 ± 0.04 (6)		1.3 ± 0.05 (6)		24 ± 5.9 (5)		51 ± 1.7 (6)	
GluNI-R794Q/GluN2A	0.68 \pm 0.06 (6)*	21	0.92 \pm 0.09 (6)*	71	31 ± 5.4 (6)	129	47 ± 0.9 (6)	92
WT GluN1/GluN2B	1.7 ± 0.12 (7)		0.33 ± 0.05 (6)		18 ± 0.53 (6)		16 ± 0.6 (5)	
GluNI-R794Q//GluN2B	0.21 \pm 0.03 (14)*	12	0.20 ± 0.02 (12)*	61	17 ± 1.7 (7)	94	17 ± 1.0 (7)	106
WT GluN1/GluN2A	3.2 ± 0.04 (6)		1.3 \pm 0.01 (7)		24 ± 5.9 (5)		$48\pm6.4~(5)$	
GluNI-N674I/GluN2A	2.2 ± 0.14 (6)	69	1.6 ± 0.08 (6)	123	34 ± 5.3 (6)	142	72 ± 3.2 (6)*	150
WT GluN1/GluN2B	1.5 \pm 0.17 (10)		0.38 ± 0.06 (6)		26 ± 3.7 (8)		16 ± 0.9 (6)	
GluNI-N674I/GluN2B	1.9 \pm 0.15 (14)	126	0.86 \pm 0.05 (11)*	226	24 ± 2.6 (6)	92	$50\pm$ 1.3 (6)*	313
WT GluN1/GluN2A	$3.9\pm0.28~(10)$		1.0 \pm 0.11 (11)		29 ± 4.1 (10)		$52\pm$ I.I (12)	
GluNI-R659W/GluN2A	0.43 \pm 0.03 (18)*	11	0.36 \pm 0.09 (10)*	36	$37\pm3.5~(7)$	128	$70 \pm 1.6 \ (11)^{*}$	135
WT GluN1/GluN2B	1.3 ± 0.09 (9)		0.33 \pm 0.03 (12)		18 ± 0.5 (6)		16 \pm 0.8 (10)	
GluNI-R659W/GluN2B	0.25 \pm 0.04 (11)*	19	0.05 \pm 0.01 (14)*	15	20 ± 3.4 (6)	111	15 \pm 1.7 (10)	94
WT GluN1/GluN2A	3.8 ± 0.51 (6)		1.3 \pm 0.06 (9)		24 ± 3.1 (6)		41 \pm 2.0 (6)	
GluNI-Y647C/GluN2A	0.06 ± 0.03 (5)*	1.6	0.06 \pm 0.01 (6)*	4.6	9.0 ± 1.0 (5)*	38	35 ± 2.1 (6)*	85
WT GluN1/GluN2B	$1.7\pm0.08~(7)$		0.41 \pm 0.05 (6)		21 ± 3.1 (5)		15 ± 2.5 (6)	
GluNI-Y647C/GluN2B	0.04 ± 0.01 (6)*	2.4	0.046 ± 0.015 (9)*	П	$17\pm4.3~(6)$	81	30 ± 3.5 (6)*	200

Data were from two-electrode voltage-clamp recordings on Xenopus oocytes at -40 mV holding potential (except for Mg²⁺ at -60 mV) and expressed as mean \pm SEM (n); WT = wild-type; *P < 0.05, unpaired t-test, compared to the corresponding data from wild-type receptors recorded on the same day.

The p.Asn674Ile mutant had a different profile of effects. The EC₅₀ for glycine was unchanged for GluN1-N674I/ GluN2A but increased to 226% for GluN1-N674I/ GluN2B (Table 3 and Fig. 3A). This indicated a reduced potency for glycine. The EC_{50} of glutamate was not significantly altered for GluN1-N674I/GluN2A or GluN1-N674I/ GluN2B (Table 3 and Fig. 3B). However, p.Asn674Ile did demonstrate significantly reduced proton inhibition (72% GluN1-N674I/GluN2A versus 48% wild-type GluN1/ GluN2A; 50% GluN1-N674I/GluN2B versus 16% wildtype GluN1/GluN2B). There was no significant difference in Mg²⁺ blockade for p.Asn674Ile receptors. To confirm that p.Asn674Ile reduced glycine potency we assessed the mutation in a second, separate in vitro heterologous expression setting. We co-expressed wild-type and mutant GluN1 with human GluN2B in HEK 293 cells and evaluated the concentration-effect curves for agonist (NMDA) and coagonist (glycine) using whole-cell voltage clamp. The whole-cell voltage clamp results (Fig. 3C and D) were consistent with the two-electrode voltage clamp findings and demonstrated a pronounced loss of sensitivity to glycine (EC₅₀ 310% of wild-type; GluN1-N674I/Glu2B: 0.93 µM, n = 8; versus wild-type GluN1/Glu2B: 0.30 μ M, n = 8; P < 0.0001; unpaired *t*-test) and a moderate reduction in the potency of NMDA (EC₅₀ 164% of wild-type; GluN1-N674I/Glu2B: 19.71 μ M, n = 6; versus wild-type GluN1/ Glu2B: 12.05 μ M, n = 8; P = 0.01; unpaired *t*-test).

Multiple attempts (mutagenesis, RNA syntheses, RNA injection, and recordings) were made to express p.Asp789Asn mutant receptors (as both GluN1/GluN2A and GluN1/GluN2B) in *Xenopus* oocytes. The current amplitudes at saturating agonist concentrations (up to 1 mM glutamate and 3 mM glycine at holding potential

of $-40 \,\mathrm{mV}$) were too small to characterize the effects on NMDA receptor pharmacological properties (GluN1-D789N/Glu2A: 13 ± 2.8 nA, n = 14; versus wild-type GluN1/Glu2A: 855 ± 199 nA, n = 14; GluN1-D789N/ Glu2B: 11 ± 3.1 nA, n = 14; versus wild-type GluN1/ Glu2B: 585 ± 156 nA, n = 14). We therefore evaluated the expression levels of GluN1-D789N using a β-lactamase activity assay in transiently-transfected HEK cells (Supplementary material) (Swanger et al., 2016). The ratio of surface-to-total protein levels for the mutant GluN1-D789N was reduced to 71 ± 4.2 % (n = 4; P = 0.04; unpaired *t*-test) of wild-type when co-expressed with wild-type GluN2A, and had no significant change $(115 \pm 46 \%; n = 8; P = 0.46; unpaired t-test)$ when co-expressed with wild-type GluN2B (Supplementary Fig. 2), suggesting that the complete loss of current responses for GluN1-D789N is not due to a trafficking defect or lack of surface expression but rather a functional change in the membrane-bound receptor.

Discussion

By using exome data from parent-offspring trios we identified 2 of 57 polymicrogyria patients with *de novo* missense mutations in *GRIN1*. Another nine *de novo* missense *GRIN1* mutations were identified in additional MCD patients. Shared features in the patients were extensive bilateral polymicrogyria, severe or profound developmental delay, postnatal microcephaly, cortical visual impairment and treatment-resistant epilepsy. *De novo* missense mutations in *GRIN1* have previously been reported in patients with non-syndromic intellectual disability (Hamdan *et al.*,




Figure 3 The p.Asn674lle mutation changes the response of the NMDA receptor to agonists. The *top* graphs display concentrationresponse curves for (**A**) glycine (in the presence of 100 μ M glutamate) and (**B**) glutamate (in the presence of 100 μ M glycine) determined by twoelectrode voltage-clamp recordings from *Xenopus* oocytes expressing either wild-type (WT)-GluN1/GluN2B or GluN1-N6741 /GluN2B. The *bottom* graphs display concentration-response curves for (**C**) glycine (in the presence of 100 μ M NMDA) and (**D**) NMDA (in the presence of 100 μ M glycine) determined by whole-cell voltage-clamp recordings from transfected HEK 293 cells expressing either WT-GluN1/GluN2B or GluN1-N6741 /GluN2B. Error bars represent SEM.

2011; Redin et al., 2014; Zhu et al., 2015; Lemke et al., 2016; Rossi et al., 2017), movement disorders (Ohba et al., 2015; Chen et al., 2017a; Zehavi et al., 2017), epileptic encephalopathy (Epi4K Consortium et al., 2013), and cerebral visual impairment (Bosch et al., 2016). The MRI features seen in previous GRIN1 patients were non-specific volume loss and generalized cerebral atrophy but not polymicrogyria (Lemke et al., 2016). We note that at least two previous GRIN1 patients only had CT brain scans, which cannot reliably detect polymicrogyria. This raises the possibility that some previous GRIN1 patients may have had unrecognized polymicrogyria. It is also possible that apparently non-polymicrogyria GRIN1 patients (by MRI) may have subtle structural brain abnormalities that are below the resolution of current scanning technology.

The NMDA receptor is a tetrameric heteromultimer that comprises two GluN1 subunits (encoded by *GRIN1*) and two variable GluN2 subunits, which are encoded by *GRIN2A*, *GRIN2B*, *GRIN2C* or *GRIN2D*. Like GluN1, GluN2B is extensively expressed in the cerebral cortex during foetal development (Liu *et al.*, 2004). *GRIN2B* mutations have been found in patients with autism (O'Roak *et al.*, 2011; Tarabeux *et al.*, 2011), cerebral visual impairment (Bosch *et al.*, 2016), West syndrome (Lemke *et al.*, 2014) and intellectual disability (Endele

et al., 2010; Adams et al., 2014; Lemke et al., 2014; Hu et al., 2016; Swanger et al., 2016). GRIN2B mutations have also recently been observed in MCD patients (Platzer et al., 2017). In contrast to the foetus, the main GluN2 subunit of the adult brain is GluN2A. This change occurs during early postnatal development and is thought to be a key developmental switch (Liu et al., 2004). GRIN2A mutations have been found in patients with epilepsy-aphasia spectrum disorders (Carvill et al., 2013; Lemke et al., 2013; Lesca et al., 2013; Gao et al., 2017), early-onset epileptic encephalopathy (Endele et al., 2010; Pierson et al., 2014; Yuan et al., 2014; Swanger et al., 2016) and schizophrenia (Tarabeux et al., 2011). However, consistent with its mainly postnatal expression, GRIN2A mutations have not been reported to cause MCDs.

The reason why some *GRIN1* patients get polymicrogyria is uncertain. This may require additional factors in the patient's genetic background or environmental conditions during gestation. Only two of our series were known to have had testing for cytomegalovirus. Patient 5 had negative postnatal serology. Patient 6 had positive testing (urine PCR and serum IgM) at 4 months of age. However, his mother had negative serology at 36 weeks, which suggests the infection occurred postnatally. Other patients were not tested because they lacked typical features of

cytomegalovirus infection (e.g. rash, retinitis, brain calcification or deafness). It has not been possible to retrospectively screen the other patients for cytomegalovirus. We observed that polymicrogyria-associated GRIN1 mutations clustered in the S2 or M3 domains, regions that are significantly depleted of variation in control populations (Swanger et al., 2016; Ogden et al., 2017). In addition, the GluN1 S2 domain has rarely been mutated in nonpolymicrogyria GRIN1 patients. The GluN1 S2 domain is critical to the binding of glycine, the co-agonist of the NMDA receptor. Therefore, the observation of this putative genotype-phenotype correlation suggests that polymicrogyria and non-polymicrogyria mutations may have different effects on co-agonist binding or the activation state of the receptor. Inspecting the 3D model of GluN1 suggests the polymicrogyria-associated mutations in S2 reside close to the extracellular end of the M3 transmembrane helix that forms a bundle crossing that occludes ion permeation. These variants may therefore alter gating. The polymicrogyria-associated p.Arg659Trp mutation was located in the DRPEER motif of S2. This motif is a highly charged motif thought to influence the relative permeability of Ca²⁺ ions through the channel (Watanabe et al., 2002). Similarly, the three M3 mutations (p.Tyr647Cys, p.Asn650Ile and p.Ala653Gly) had milder effects on the wider structure of the receptor but were located in the highly-conserved Lurcher motif, which controls NMDA receptor gating.

Our structural modelling found polymicrogyria-associated mutations were associated with an increase in the average number of hydrogen bonds between the glycine ligand and the glycine-binding residues of GluN1. The formation of additional hydrogen bonds may alter the kinetics of co-agonist binding (e.g. increased affinity). No other stark differences between polymicrogyria-associated and previous *GRIN1* mutations were observed. The measurements used (transmembrane helix position and domain-specific RMSD) may not have been sensitive to key differences between the two groups. In addition, the structural modelling suggests there is heterogeneity in how polymicrogyriaassociated mutations affect GluN1 structure. This may have confounded comparison between the two groups.

Two-electrode voltage clamp analysis showed that three of the polymicrogyria-associated mutations (p.Tyr647Cys, p.Arg659Trp and p.Arg794Gln) significantly increased the potency of both glutamate and glycine. This increased potency may mean that mutant receptors can be activated at lower concentrations of agonist than wild-type receptor. Several lines of evidence link excess NMDA receptor signalling to polymicrogyria. The intracerebral injection of ibotenate has been used for decades to generate *in vivo* models of epilepsy and cortical malformations including polymicrogyria (Marret *et al.*, 1996; Takano *et al.*, 2004). Ibotenate is an agonist of both NMDA and glutamatergic metabotropic receptors. Intracerebral ibotenate injection in newborn mice (Marret *et al.*, 1995), hamsters (Marret *et al.*, 1996; Takano *et al.*, 2004) and rats

(Takano and Matsui, 2015) causes a range of grey and white matter changes, including polymicrogyria-like lesions, similar to those seen following perinatal hypoxic/ischaemic insults. Over-stimulation of NMDA receptors is thought to lead to excitotoxicity due to excess calcium influx through the receptor channel (Choi et al., 1988; Zhou et al., 2013). Profound gain-of-function NMDA receptor subunit mutations are excitotoxic when expressed in vitro (Li et al., 2016; Ogden et al., 2017). NMDA receptor-related excitotoxicity has been implicated in hypoxic/ischaemic events (Simon et al., 1984; Rothman and Olney, 1986). Hypoxic/ischaemic events during foetal brain development are a well-recognized cause of polymicrogyria in humans. Calcium influx through the NMDA receptor can lead to activation of a range of cellular pathways including the pro-survival PI3K-AKT pathway (Lafon-Cazal et al., 2002; Wang et al., 2012). Activating mutations in components of the PI3K-AKT pathway have been found in polymicrogyria patients (Riviere et al., 2012; Mirzaa et al., 2014). MCDs including polymicrogyria are a feature of Zellweger syndrome, a rare metabolic disorder caused by peroxisomal dysfunction. Analysis of a mouse model of Zellweger syndrome showed that the neuronal migration abnormalities seen in the mice were due to NMDA receptor-mediated calcium mobilization (Gressens et al., 2000). Another metabolic disorder associated with polymicrogyria is glycine encephalopathy (Dobyns, 1989). The hyperglycinaemia in this condition may enhance the excitotoxic activity of glutamate acting through the NMDA receptor (Subramanian et al., 2015).

In contrast to the three potential gain-of-function polymicrogyria-associated GRIN1 mutations, most previous GRIN1 mutations caused dominant-negative effects resulting in a significant loss of receptor function (Lemke et al., 2016). Animal models suggest that NMDA receptor hypofunction is less likely to disturb gross cortical structure. Mice homozygous for GluN1 null alleles die soon after birth from respiratory problems but do not have severe abnormalities of neuronal migration (Messersmith et al., 1997). Similarly, mice with a GluN1 deletion limited to excitatory cortical neurons have only subtle disturbance of cortical structure (Iwasato et al., 2000). However, a simple model of gain-of-function GRIN1 mutations causing polymicrogyria is challenged by the results for p.Asn674Ile. Both two-electrode and whole-cell voltage clamp analyses were consistent in showing this mutation decreased the potency of glycine and possibly (to a lesser extent) glutamate. How can we explain this apparently paradoxical finding? There are a number of possible mechanisms that might explain why p.Asn674Ile causes polymicrogyria.

First, the p.Asn674Ile mutation caused a significant loss of proton inhibition. GluN2B receptors are inhibited with an IC_{50} at physiological pH. Therefore loss of proton inhibition will potentiate responses even at resting pH. This may mean neurons are prone to excess calcium influx, a problem that will be exacerbated in low pH environments (e.g. during oxidative stress). Recent work has shown the

importance of the balance of signalling through synaptic and extra-synaptic NMDA receptors (Zhou et al., 2015). Activation of synaptic NMDA receptors activates pro-survival pathways. In contrast, massive and prolonged co-activation of both synaptic and extrasynaptic receptors leads to cell death. If p.Asn674Ile blunts the response of synaptic receptors (e.g. through reduced agonist potency) while promoting signalling at extrasynaptic receptors (e.g. through reduced proton inhibition) this may tip the balance in some neurons towards apoptosis. Alternatively, polymicrogyria may be a consequence of disturbed NMDA receptor signalling regardless of whether there is gain- or loss-offunction. There is evidence from in vitro studies that a low-level background of NMDA activation is needed to support neuronal survival (Zhou et al., 2015), guide radial migration (Behar et al., 1999; Hirai et al., 1999) and promote neuronal differentiation (Yoneyama et al., 2008). Transient delivery of an NMDA antagonist to a focal area of the cortex of newborn rats disturbs cortical lamination and generates heterotopic cell clusters (Reiprich et al., 2005). A range of NMDA antagonists, including ethanol, have been shown to induce apoptosis in the brains of developing rats (Olney et al., 2002). This is of relevance as polymicrogyria has occasionally been reported in patients with foetal alcohol syndrome (Reinhardt et al., 2010). Finally, it remains possible that p.Asn674Ile (and other polymicrogyria-associated GRIN1 mutations) may have additional effects that have not been captured by our electrophysiological analysis.

If polymicrogyria-associated GRIN1 mutations mainly cause gain of function while non-polymicrogyria mutations cause loss of function it raises the question why the two types cause such similar phenotypes (severe developmental delay, spasticity, early onset seizures, postnatal microcephaly, cerebral visual impairment and stereotypic movements). A potential explanation is that gain-of-function mutations may cause cell death (due to excitotoxicity) soon after neurons begin expressing NMDA receptors. Early cell loss would thin the foetal cortex (leading to polymicrogyria) and result in a postnatal cortex depleted of cells expressing NMDA receptors. In contrast, loss-of-function mutations may cause cell death more gradually (e.g. due to loss of NMDA-mediated pro-survival signalling) missing the key window when polymicrogyria occurs (<22 weeks). Having cells in the postnatal cortex which are insensitive to glutamate (due to loss-of-function mutations) may be functionally equivalent to the cells being absent (due to gain-of-function mutations). The evidence of cerebral atrophy observed in several patients was present in infancy and progressed on subsequent scans (Patient 11). The atrophy is likely due to the direct effects of mutations (excitotoxicity or loss of prosurvival signalling) as well as damage from frequent seizures.

In conclusion, we have found *de novo GRIN1* missense mutations in patients with extensive bilateral polymicrogyria. Our results provide evidence for a genotype–pheno-type correlation with most polymicrogyria-associated *GRIN1* mutations clustering in the S2 or M3 domains,

regions of the protein rarely mutated in non-polymicrogyria patients or the normal population. In addition, we showed that polymicrogyria-associated *GRIN1* mutations significantly alter *in vitro* NMDA receptor function. Our results confirm the importance of *de novo* mutations in the aetiology of MCDs and polymicrogyria; expand the phenotypic spectrum associated with *GRIN1* mutations; demonstrate similarities between human polymicrogyria and animal models of the disorder; and highlight the important role of NMDA signalling in the pathogenesis of polymicrogyria.

Acknowledgements

The authors would like to thank the patients, families, clinicians and scientists who contributed to this work. We would particularly like to thank the *GRIN1* family group for providing access to the MRI scans of their members.

Funding

This work was funded by the Newlife Foundation for Disabled Children (Grant Reference: 11-12/04). This publication is a result of the European Network on Brain Malformations (COST Action CA16118), a network funded by COST (European Cooperation in Science and Technology). The project was also supported by the Wales Epilepsy Research Network and the Wales Gene Park. H.Y. was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development under Award Number R01HD082373; S.F.T. was supported by NIH-NINDS R01NS036654, R01NS065371, and R24NS092989. G.M.M. was supported by NIH-NINDS K08NS092898. We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z and Medical Research Council Hub grant G0900747 91070) for the generation of the Sequencing data. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Supplementary material

Supplementary material is available at Brain online.

References

- Adams DR, Yuan H, Holyoak T, Arajs KH, Hakimi P, Markello TC, et al. Three rare diseases in one Sib pair: RAI1, PCK1, GRIN2B mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity. Mol Genet Metab 2014; 113: 161–70.
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248–9.

- Behar TN, Scott CA, Greene CL, Wen X, Smith SV, Maric D, et al. Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J Neurosci 1999; 19: 4449–61.
- Bosch DG, Boonstra FN, de Leeuw N, Pfundt R, Nillesen WM, de Ligt J, et al. Novel genetic causes for cerebral visual impairment. Eur J Hum Genet 2016; 24: 660–5.
- Carvill GL, Regan BM, Yendle SC, O'Roak BJ, Lozovaya N, Bruneau N, et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet 2013; 45: 1073–6.
- Chen W, Shieh C, Swanger SA, Tankovic A, Au M, McGuire M, et al. GRIN1 mutation associated with intellectual disability alters NMDA receptor trafficking and function. J Hum Genet 2017a; 62: 589–97.
- Chen W, Tankovic A, Burger PB, Kusumoto H, Traynelis SF, Yuan H. Functional evaluation of a *de novo* GRIN2A mutation identified in a patient with profound global developmental delay and refractory epilepsy. Mol Pharmacol 2017b; 91: 317–30.
- Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 1988; 8: 185–96.
- Dobyns WB. Agenesis of the corpus callosum and gyral malformations are frequent manifestations of nonketotic hyperglycinemia. Neurology 1989; 39: 817–20.
- Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 2010; 42: 1021–6.
- Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen AS, Berkovic SF, Cossette P, Delanty N, et al. *De novo* mutations in epileptic encephalopathies. Nature 2013; 501: 217–21.
- Gao K, Tankovic A, Zhang Y, Kusumoto H, Zhang J, Chen W, et al. A *de novo* loss-of-function GRIN2A mutation associated with child-hood focal epilepsy and acquired epileptic aphasia. PLoS One 2017; 12: e0170818.
- Gressens P, Baes M, Leroux P, Lombet A, Van Veldhoven P, Janssen A, et al. Neuronal migration disorder in Zellweger mice is secondary to glutamate receptor dysfunction. Ann Neurol 2000; 48: 336–43.
- Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K, et al. Excess of *de novo* deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 2011; 88: 306–16.
- Hansen KB, Tajima N, Risgaard R, Perszyk RE, Jørgensen L, Vance KM, et al. Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors. Mol Pharmacol 2013; 84: 114–27.
- Hedegaard M, Hansen KB, Andersen KT, Brauner-Osborne H, Traynelis SF. Molecular pharmacology of human NMDA receptors. Neurochem Int 2012; 61: 601–9.
- Hirai K, Yoshioka H, Kihara M, Hasegawa K, Sakamoto T, Sawada T, et al. Inhibiting neuronal migration by blocking NMDA receptors in the embryonic rat cerebral cortex: a tissue culture study. Brain Res Dev Brain Res 1999; 114: 63–7.
- Hu C, Chen W, Myers SJ, Yuan H, Traynelis SF. Human GRIN2B variants in neurodevelopmental disorders. J Pharmacol Sci 2016; 132: 115–21.
- Iwasato T, Datwani A, Wolf AM, Nishiyama H, Taguchi Y, Tonegawa S, et al. Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. Nature 2000; 406: 726–31.
- Jagadeesh KA, Wenger AM, Berger MJ, Guturu H, Stenson PD, Cooper DN, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet 2016; 48: 1581–6.
- Jaglin XH, Poirier K, Saillour Y, Buhler E, Tian G, Bahi-Buisson N, et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat Genet 2009; 41: 746–52.
- Jansen A, Andermann E. Genetics of the polymicrogyria syndromes. J Med Genet 2005; 42: 369–78.

- Jansen AC, Robitaille Y, Honavar M, Mullatti N, Leventer RJ, Andermann E, et al. The histopathology of polymicrogyria: a series of 71 brain autopsy studies. Dev Med Child Neurol 2016; 58: 39–48.
- Jiang LH, Rassendren F, Mackenzie A, Zhang YH, Surprenant A, North RA. N-methyl-D-glucamine and propidium dyes utilize different permeation pathways at rat P2X(7) receptors. Am J Physiol Cell Physiol 2005; 289: C1295–302.
- Karakas E, Furukawa H. Crystal structure of a heterotetrameric NMDA receptor ion channel. Science 2014; 344: 992–7.
- Kiezun A, Garimella K, Do R, Stitziel NO, Neale BM, McLaren PJ, et al. Exome sequencing and the genetic basis of complex traits. Nat Genet 2012; 44: 623–30.
- Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014; 46: 310–5.
- Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073–81.
- Lafon-Cazal M, Perez V, Bockaert J, Marin P. Akt mediates the antiapoptotic effect of NMDA but not that induced by potassium depolarization in cultured cerebellar granule cells. Eur J Neurosci 2002; 16: 575–83.
- Law AJ, Weickert CS, Webster MJ, Herman MM, Kleinman JE, Harrison PJ. Expression of NMDA receptor NR1, NR2A and NR2B subunit mRNAs during development of the human hippocampal formation. Eur J Neurosci 2003; 18: 1197–205.
- Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016; 536: 285–91.
- Lemke JR, Geider K, Helbig KL, Heyne HO, Schutz H, Hentschel J, et al. Delineating the GRIN1 phenotypic spectrum: a distinct genetic NMDA receptor encephalopathy. Neurology 2016; 86: 2171–8.
- Lemke JR, Hendrickx R, Geider K, Laube B, Schwake M, Harvey RJ, et al. GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. Ann Neurol 2014; 75: 147–54.
- Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, Alber M, et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet 2013; 45: 1067–72.
- Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-Kryza N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013; 45: 1061– 6.
- Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick EM, et al. GRIN2D recurrent *de novo* dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet 2016; 99: 802–16.
- Liu XB, Murray KD, Jones EG. Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J Neurosci 2004; 24: 8885–95.
- Marret S, Gressens P, Evrard P. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc Natl Acad Sci USA 1996; 93: 15463–8.
- Marret S, Mukendi R, Gadisseux JF, Gressens P, Evrard P. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol 1995; 54: 358–70.
- Messersmith EK, Feller MB, Zhang H, Shatz CJ. Migration of neocortical neurons in the absence of functional NMDA receptors. Mol Cell Neurosci 1997; 9: 347–57.
- Mirzaa GM, Parry DA, Fry AE, Giamanco KA, Schwartzentruber J, Vanstone M, et al. *De novo* CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactylyhydrocephalus syndrome. Nat Genet 2014; 46: 510–5.
- Mullins JG. Structural modelling pipelines in next generation sequencing projects. Adv Protein Chem Struct Biol 2012; 89: 117–67.

- Murthy SE, Shogan T, Page JC, Kasperek EM, Popescu GK. Probing the activation sequence of NMDA receptors with lurcher mutations. J Gen Physiol 2012; 140: 267–77.
- Notredame C, Higgins DG, Heringa J. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol 2000; 302: 205–17.
- O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe *de novo* mutations. Nat Genet 2011; 43: 585–9.
- Ogden KK, Chen W, Swanger SA, McDaniel MJ, Fan LZ, Hu C, et al. Molecular mechanism of disease-associated mutations in the pre-M1 helix of NMDA receptors and potential rescue pharmacology. PLoS Genet 2017; 13: e1006536.
- Ohba C, Shiina M, Tohyama J, Haginoya K, Lerman-Sagie T, Okamoto N, et al. GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. Epilepsia 2015; 56: 841–8.
- Olney JW, Wozniak DF, Jevtovic-Todorovic V, Farber NB, Bittigau P, Ikonomidou C. Drug-induced apoptotic neurodegeneration in the developing brain. Brain Pathol 2002; 12: 488–98.
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605–12.
- Pierson TM, Yuan H, Marsh ED, Fuentes-Fajardo K, Adams DR, Markello T, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 2014; 1: 190–8.
- Platzer K, Yuan H, Schütz H, Winschel A, Chen W, Hu C, et al. GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J Med Genet 2017; 54: 460–70.
- Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res 2010; 20: 110–21.
- Redin C, Gérard B, Lauer J, Herenger Y, Muller J, Quartier A, et al. Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. J Med Genet 2014; 51: 724–36.
- Reinhardt K, Mohr A, Gartner J, Spohr HL, Brockmann K. Polymicrogyria in fetal alcohol syndrome. Birth Defects Res A Clin Mol Teratol 2010; 88: 128–31.
- Reiprich P, Kilb W, Luhmann HJ. Neonatal NMDA receptor blockade disturbs neuronal migration in rat somatosensory cortex *in vivo*. Cereb Cortex 2005; 15: 349–58.
- Riviere JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, et al. *De novo* germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 2012; 44: 934–40.
- Rossi M, Chatron N, Labalme A, Ville D, Carneiro M, Edery P, et al. Novel homozygous missense variant of GRIN1 in two sibs with intellectual disability and autistic features without epilepsy. Eur J Hum Genet 2017; 25: 376–80.
- Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic—ischemic brain damage. Ann Neurol 1986; 19: 105–11.
- Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014; 11: 361–2.
- Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 1984; 226: 850–2.
- Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 2009; 462: 745–56.

- Squier W, Jansen A. Polymicrogyria: pathology, fetal origins and mechanisms. Acta Neuropathol Commun 2014; 2: 80.
- Stutterd CA, Leventer RJ. Polymicrogyria: a common and heterogeneous malformation of cortical development. Am J Med Genet C Semin Med Genet 2014; 166C: 227–39.
- Subramanian V, Kadiyala P, Hariharan P, Neeraj E. A rare case of glycine encephalopathy unveiled by valproate therapy. J Pediatr Neurosci 2015; 10: 143–5.
- Swanger SA, Chen W, Wells G, Burger PB, Tankovic A, Bhattacharya S, et al. Mechanistic insight into NMDA receptor dysregulation by rare variants in the GluN2A and GluN2B agonist binding domains. Am J Hum Genet 2016; 99: 1261–80.
- Takano T, Matsui K. Increased expression of GAP43 in interneurons in a rat model of experimental polymicrogyria. J Child Neurol 2015; 30: 716–28.
- Takano T, Sawai C, Takeuchi Y. Radial and tangential neuronal migration disorder in ibotenate-induced cortical lesions in hamsters: immunohistochemical study of reelin, vimentin, and calretinin. J Child Neurol 2004; 19: 107–15.
- Tarabeux J, Kebir O, Gauthier J, Hamdan FF, Xiong L, Piton A, et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry 2011; 1: e55.
- Thompson BA, Storm MP, Hewinson J, Hogg S, Welham MJ, MacKenzie AB. A novel role for P2X7 receptor signalling in the survival of mouse embryonic stem cells. Cell Signal 2012; 24: 770–8.
- Wang YB, Wang JJ, Wang SH, Liu SS, Cao JY, Li XM, et al. Adaptor protein APPL1 couples synaptic NMDA receptor with neuronal prosurvival phosphatidylinositol 3-kinase/Akt pathway. J Neurosci 2012; 32: 11919–29.
- Watanabe J, Beck C, Kuner T, Premkumar LS, Wollmuth LP. DRPEER: a motif in the extracellular vestibule conferring high Ca2+ flux rates in NMDA receptor channels. J Neurosci 2002; 22: 10209–16.
- Webb B, Sali A. Comparative protein structure modeling using modeller. Curr Protoc Bioinformatics 2016; 54: 5.6.1–5.6.37.
- Yoneyama M, Nakamichi N, Fukui M, Kitayama T, Georgiev DD, Makanga JO, et al. Promotion of neuronal differentiation through activation of N-methyl-D-aspartate receptors transiently expressed by undifferentiated neural progenitor cells in fetal rat neocortex. J Neurosci Res 2008; 86: 2392–402.
- Yuan H, Erreger K, Dravid SM, Traynelis SF. Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J Biol Chem 2005; 280: 29708–16.
- Yuan H, Hansen KB, Zhang J, Pierson TM, Markello TC, Fajardo KV, et al. Functional analysis of a *de novo* GRIN2A missense mutation associated with early-onset epileptic encephalopathy. Nat Commun 2014; 5: 3251.
- Zehavi Y, Mandel H, Zehavi A, Rashid MA, Straussberg R, Jabur B, et al. *De novo* GRIN1 mutations: an emerging cause of severe early infantile encephalopathy. Eur J Med Genet 2017; 60: 317–320.
- Zhou X, Chen Z, Yun W, Ren J, Li C, Wang H. Extrasynaptic NMDA receptor in excitotoxicity: function revisited. Neuroscientist 2015; 21: 337–44.
- Zhou X, Hollern D, Liao J, Andrechek E, Wang H. NMDA receptormediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis 2013; 4: e560.
- Zhu X, Petrovski S, Xie P, Ruzzo EK, Lu YF, McSweeney KM, et al. Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Genet Med 2015; 17: 774–81.